• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Microbiol . Comparing Five SARS-CoV-2 Antibody Assay Results Before and After the First and Second ChAdOx1 nCoV-19 Vaccination Among Health

tetano

tetano

Editor, Senior Moderator
  1. J Clin Microbiol
  4. . 2021 Oct 6;JCM0178821.
  5. doi: 10.1128/JCM.01788-21. Online ahead of print.
  6. Comparing Five SARS-CoV-2 Antibody Assay Results Before and After the First and Second ChAdOx1 nCoV-19 Vaccination Among Health Care Workers: A Prospective Multicenter Study

Seri Jeong[SUP] 1 [/SUP], Nuri Lee[SUP] 1 [/SUP], Su Kyung Lee[SUP] 2 [/SUP], Eun-Jung Cho[SUP] 2 [/SUP], Jungwon Hyun[SUP] 2 [/SUP], Min-Jeong Park[SUP] 1 [/SUP], Wonkeun Song[SUP] 1 [/SUP], Eun Ju Jung[SUP] 3 [/SUP], Heungjeong Woo[SUP] 3 [/SUP], Yu Bin Seo[SUP] 4 [/SUP], Jin Ju Park[SUP] 4 [/SUP], Hyun Soo Kim[SUP] 2 [/SUP]



Affiliations

Abstract

Reliable results for serologic positivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody after the second dose of AstraZeneca (AZ) vaccination are important to estimate the real efficacy of vaccination. We evaluated the positivity rates and the changes of semi-quantitative antibody titers before and after the first and second ChAdOx1 nCoV-19 Vaccinations using five SARS-CoV-2 antibody assays, including two surrogate virus neutralization tests. A total of 674 serum samples were obtained from 228 participants during three blood sampling periods. A questionnaire on symptoms, severity and adverse reactions duration was completed after the second vaccination. The overall positive rates for all assays were 0.0-0.9% before vaccination, 66.2-92.5% after the first vaccination, and 98.2-100.0% after the second vaccination. Median antibody titers in five assays after the second dose of vaccination were increased compared to those after the first dose (106.4-fold increase for Roche total antibody, 3.6-fold for Abbott IgG, 3.6-fold for Siemens, 1.2-fold for SD Biosensor V1 neutralizing antibody, and 2.2-fold for GenScript neutralizing antibody). Adverse reactions reduced after the second dose in 89.9% of participants compared to after the first dose. Overall, the second vaccination led to almost 100% positivity rates based on these SARS-CoV-2 antibody assays. The results should be interpreted with caution, considering the characteristics of applied assays. Our findings could inform decisions regarding vaccination and the use of immunoassays, thus, contributing to the SARS-CoV-2 pandemic control.
 
You must log in or register to reply here.
Back
Top Bottom